Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 in Obesity
NCT07508020Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NNC0487-0111 with Placebo (2 arms). Primary endpoint: Relative change from baseline in total energy intake across ad libitum breakfast, lunch, evening meal and snack box at Day 238. Started Mar 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07508020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508020.